Hervé Avet-Loiseau

23PUBLICATIONS
227CO-AUTHORS
Medical mycologyAutoimmunityPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Feb 25, 2026
Patient-Centered Education Through A Massive Open Online Course (MOOC) for Patients With Multiple Myeloma and Caregivers: Descriptive Study of Knowledge Gains by French Association of Patients With Multiple Myeloma (AF3M) and French-Speaking Myeloma Intergroup (IFM).

Alexis Talbot, Bernard Delcour, Laurent Gillot

|Dec 11, 2025
Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.

Anil Aktas Samur, Jill Corre, Srikanth Talluri

|Jun 09, 2025
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.

Hervé Avet-Loiseau, Faith E Davies, Mehmet K Samur

|Jan 22, 2025
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial.

Aurore Perrot, Cyrille Touzeau, Jerome Lambert

|Nov 21, 2024
Development of hyperdiploidy starts at an early age and takes a decade to complete.

Mehmet K Samur, Anil Aktas Samur, Parth Shah

|Jun 14, 2024
NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma.

Eve Blanquart, Rüçhan Ekren, Bineta Rigaud

Pageof 4

Frequent Collaborators

14 joint publications

Jill Corre

8 joint publications

Aurore Perrot

5 joint publications

Jesus San-Miguel

4 joint publications

Nikhil Munshi